The CJC-1295/ipamorelin combination is the most-sold protocol in the GH secretagogue category. It is also the one where the regulatory picture is murkiest and where marketing most consistently conflates two different molecules. Worth understanding before you compare it to anything.
Two receptors, one output
Growth hormone release is governed by more than one input. GHRH analogs work on the pituitary GHRH receptor. GHRPs — growth hormone releasing peptides — work on the ghrelin receptor and also blunt somatostatin, the brake on GH release.
Pull both levers and you get a larger pulse than either alone. That is the whole mechanistic case for the pairing, and it is sound as far as it goes.
| Sermorelin | CJC-1295 | Ipamorelin | |
|---|---|---|---|
| Class | GHRH analog | GHRH analog | GHRP / ghrelin agonist |
| Receptor | GHRH-R | GHRH-R | GHS-R1a |
| Duration | Short | Short (no DAC) / long (DAC) | Short |
| Cortisol / prolactin | Minimal | Minimal | Comparatively selective |
| Appetite effect | Minimal | Minimal | Low for the class |
| FDA-approved product | None current (Geref, withdrawn 2008) | None | None |
The DAC distinction that gets buried
CJC-1295 with DAC carries a drug affinity complex that binds albumin and stretches half-life into days, producing a sustained elevation often described as a GH bleed. CJC-1295 without DAC (frequently sold as modified GRF 1-29) is short-acting and produces a discrete pulse.
These behave differently, are dosed differently, and are routinely sold under the same three-character name. If a product page does not specify, that is a data point about the seller.
The pulsatility argument cuts against the DAC version specifically. The natural GH rhythm is pulsatile, with the largest burst during slow-wave sleep, and negative feedback is built around that pattern. A sustained elevation overrides the rhythm rather than amplifying it. Whether that matters clinically is debated; that it is a real mechanistic difference is not.
Where ipamorelin earns its place
Older GHRPs are effective and messy — GHRP-6 in particular is notorious for driving appetite, and the class has historically carried cortisol and prolactin effects. Ipamorelin is comparatively selective, which is why it displaced the older options in most protocols. It is the cleanest member of a dirty class, which is a real advantage and also a limited one.
Against sermorelin
Sermorelin is a single-arm GHRH agent. The stack is a two-arm approach that produces a larger GH release. The honest framing:
- Potency: the stack, clearly.
- Regulatory clarity: sermorelin, clearly. It had an approval; the withdrawal was commercial. CJC-1295 has never had one.
- Evidence of clinical outcome: neither is strong. Both are largely justified by IGF-1 movement and mechanism rather than by outcome trials in healthy adults.
- Cost: sermorelin is the entry point; stacks cost more and involve more compounds.
Larger GH release is an input, not an outcome. Nobody trains for peak serum GH. Before comparing stack potency, it is worth asking what result you are actually buying, whether IGF-1 is a reasonable proxy for it, and whether sleep quality and training load are already maximized — because both move the GH axis more reliably than anything on this page.
Sourcing reality
These compounds exist in two channels with different rules. Prescription programs work through licensed clinicians and compounding pharmacies. The research channel sells the same names for laboratory use only, at a fraction of the price, with quality that depends entirely on the supplier’s testing discipline.
Prescription pathway
Research-use suppliers
Frequently Asked
They act on different receptors. CJC-1295 is a GHRH analog; ipamorelin is a ghrelin-receptor agonist (a GHRP). Stimulating both arms produces a larger GH release than either alone, which is the entire rationale for the pairing.
CJC-1295 is not an FDA-approved drug for human use. It is widely sold as a research compound and is also prescribed by some compounding-based programs, a status that has been the subject of ongoing regulatory attention. Treat any claim of straightforward legality with skepticism.
The DAC (drug affinity complex) modification dramatically extends half-life, producing a sustained GH elevation rather than a discrete pulse. Without DAC, the compound behaves more like a short-acting GHRH analog. The two are frequently conflated in marketing and they are not interchangeable.
Less than most. Ipamorelin is comparatively selective at the ghrelin receptor and is generally reported to have less impact on cortisol, prolactin, and appetite than older GHRPs such as GHRP-6. That selectivity is its main selling point.
It produces a larger GH release, which is a different claim from producing a better outcome. Sermorelin is a single-arm GHRH agent with a clearer regulatory story. The stack is more potent and carries more ambiguity.